Long-Acting Injectibles’ Halo Effect on all HIV Prevention Options with Yvette Raphael and Gilead Sciences, Dr. Alex Kintu

In this episode, host Ben Plumley, along with co-host Yvette Raphael, reports from the International AIDS Society Scientific Conference in Kigali, Rwanda. They discuss significant advancements in HIV prevention, particularly the recent FDA approval of Lenacapavir, with Dr. Alex Kintu from Gilead Sciences. The conversation covers the clinical journey and delivery mechanisms of Lenacapavir, its impact on young people and pregnant women, and the urgency of making this innovation widely accessible amidst funding challenges. The episode also highlights the critical role of community engagement and accountability boards in informing and driving HIV prevention strategies. Tune in for an in-depth look at the latest scientific and policy developments in the fight against HIV/AIDS.

00:00 Introduction and Welcome

00:37 Yvette's Stage Takeover Experience

01:33 Discussion on Gilead Sciences and HIV Prevention

02:15 Dr. Alex Kintu's Background and Role

03:33 FDA Approval and Next Steps for Lenacapavir

04:08 Global Access and Regulatory Processes

11:04 Understanding Lena Kavir and Its Importance

17:36 Challenges and Future of HIV Prevention

27:23 Community Engagement and Youth Involvement

34:33 Closing Remarks and Call to Action

💬 Join the Conversation!

How do you see the future of global health unfolding? Share your thoughts in the comments!

🔔Subscribe & Stay Updated:

Listen on Spotify, Apple Podcasts, or your favorite podcast platform.

Watch on YouTube & subscribe for more in-depth global health discussions:

www.youtube.com/@shotarmpodcast